Survival and response rate analysis was performed for parameters clinically relevant for metastatic colorectal cancer, such as gender, age, M0 vs. M1, number of metastatic sites, KRAS status, and primary tumor sidedness (Fig. 3). This evidence concerns the gene KRAS and metastatic colorectal cancer.